vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
Perella Weinberg Partners is the larger business by last-quarter revenue ($219.2M vs $183.1M, roughly 1.2× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 6.3%, a 7.0% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -2.9%). Perella Weinberg Partners produced more free cash flow last quarter ($30.5M vs $24.6M). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
AMPH vs PWP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $219.2M |
| Net Profit | $24.4M | $13.8M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 8.5% |
| Net Margin | 13.3% | 6.3% |
| Revenue YoY | -1.8% | -2.9% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $219.2M | ||
| Q3 25 | $191.8M | $164.6M | ||
| Q2 25 | $174.4M | $155.3M | ||
| Q1 25 | $170.5M | $211.8M | ||
| Q4 24 | $186.5M | $225.7M | ||
| Q3 24 | $191.2M | $278.2M | ||
| Q2 24 | $182.4M | $272.0M | ||
| Q1 24 | $171.8M | $102.1M |
| Q4 25 | $24.4M | $13.8M | ||
| Q3 25 | $17.4M | $6.0M | ||
| Q2 25 | $31.0M | $2.7M | ||
| Q1 25 | $25.3M | $17.3M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $16.4M | ||
| Q2 24 | $37.9M | $-66.0M | ||
| Q1 24 | $43.2M | $-35.8M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 8.5% | ||
| Q3 25 | 13.2% | 5.4% | ||
| Q2 25 | 24.2% | 5.8% | ||
| Q1 25 | 21.9% | 5.5% | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | 12.9% | ||
| Q2 24 | 30.3% | -30.2% | ||
| Q1 24 | 27.9% | -52.4% |
| Q4 25 | 13.3% | 6.3% | ||
| Q3 25 | 9.0% | 3.6% | ||
| Q2 25 | 17.8% | 1.8% | ||
| Q1 25 | 14.8% | 8.2% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 5.9% | ||
| Q2 24 | 20.8% | -24.3% | ||
| Q1 24 | 25.1% | -35.1% |
| Q4 25 | $0.51 | $0.11 | ||
| Q3 25 | $0.37 | $0.08 | ||
| Q2 25 | $0.64 | $0.04 | ||
| Q1 25 | $0.51 | $0.24 | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | $0.24 | ||
| Q2 24 | $0.73 | $-1.21 | ||
| Q1 24 | $0.81 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $255.9M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $-127.4M |
| Total Assets | $1.6B | $797.6M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $255.9M | ||
| Q3 25 | $276.2M | $185.5M | ||
| Q2 25 | $231.8M | $145.0M | ||
| Q1 25 | $236.9M | $111.2M | ||
| Q4 24 | $221.6M | $407.4M | ||
| Q3 24 | $250.5M | $335.1M | ||
| Q2 24 | $217.8M | $185.3M | ||
| Q1 24 | $289.6M | $156.7M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $-127.4M | ||
| Q3 25 | $776.7M | $-302.4M | ||
| Q2 25 | $757.5M | $-318.4M | ||
| Q1 25 | $751.3M | $-323.1M | ||
| Q4 24 | $732.3M | $-421.4M | ||
| Q3 24 | $727.7M | $-360.8M | ||
| Q2 24 | $713.3M | $-283.0M | ||
| Q1 24 | $672.4M | $161.9M |
| Q4 25 | $1.6B | $797.6M | ||
| Q3 25 | $1.7B | $650.2M | ||
| Q2 25 | $1.6B | $606.7M | ||
| Q1 25 | $1.6B | $570.5M | ||
| Q4 24 | $1.6B | $876.8M | ||
| Q3 24 | $1.5B | $810.9M | ||
| Q2 24 | $1.5B | $645.5M | ||
| Q1 24 | $1.6B | $583.6M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $34.8M |
| Free Cash FlowOCF − Capex | $24.6M | $30.5M |
| FCF MarginFCF / Revenue | 13.4% | 13.9% |
| Capex IntensityCapex / Revenue | 4.5% | 2.0% |
| Cash ConversionOCF / Net Profit | 1.35× | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $34.8M | ||
| Q3 25 | $52.6M | $59.2M | ||
| Q2 25 | $35.6M | $56.1M | ||
| Q1 25 | $35.1M | $-176.5M | ||
| Q4 24 | $29.0M | $223.4M | ||
| Q3 24 | $60.0M | $200.3M | ||
| Q2 24 | $69.1M | $90.0M | ||
| Q1 24 | $55.3M | $-206.3M |
| Q4 25 | $24.6M | $30.5M | ||
| Q3 25 | $47.2M | $57.6M | ||
| Q2 25 | $25.0M | $55.3M | ||
| Q1 25 | $24.4M | $-177.6M | ||
| Q4 24 | $16.6M | $207.0M | ||
| Q3 24 | $46.2M | $199.3M | ||
| Q2 24 | $63.1M | $83.7M | ||
| Q1 24 | $46.5M | $-214.8M |
| Q4 25 | 13.4% | 13.9% | ||
| Q3 25 | 24.6% | 35.0% | ||
| Q2 25 | 14.3% | 35.6% | ||
| Q1 25 | 14.3% | -83.8% | ||
| Q4 24 | 8.9% | 91.7% | ||
| Q3 24 | 24.1% | 71.6% | ||
| Q2 24 | 34.6% | 30.8% | ||
| Q1 24 | 27.1% | -210.3% |
| Q4 25 | 4.5% | 2.0% | ||
| Q3 25 | 2.8% | 0.9% | ||
| Q2 25 | 6.1% | 0.5% | ||
| Q1 25 | 6.3% | 0.5% | ||
| Q4 24 | 6.7% | 7.3% | ||
| Q3 24 | 7.2% | 0.4% | ||
| Q2 24 | 3.3% | 2.3% | ||
| Q1 24 | 5.1% | 8.3% |
| Q4 25 | 1.35× | 2.52× | ||
| Q3 25 | 3.03× | 9.85× | ||
| Q2 25 | 1.15× | 20.50× | ||
| Q1 25 | 1.39× | -10.18× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 12.23× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PWP
Segment breakdown not available.
